A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years

Vaccine

Volumn 29, Issue 32, 2011, Pages 5195-5202

  Schwarz, T F ^a   Flamaing, J ^b   Rumke H C ^c   Penzes, J ^d   Juergens, C ^e   Wenz, A ^e   Jayawardene, D ^e   Giardina, P ^f   Emini, E A ^f   Gruber, W C ^f   Schmoele Thoma, B ^e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c p/a Erasmus Medisch Centrum   (Netherlands)

^d Konszenzus Plusz Kft ^*  (Hungary)

^e PFIZER INC   (United States)

^f Pfizervaccine Research   (United States)

Author keywords

13 Valent pneumococcal conjugate vaccine; Europe; Immunogenicity; Safety

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

AGED; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; CHILL; CONTROLLED STUDY; DEATH; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM ULCER; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART FAILURE; HUMAN; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; JOINT LIMITATION; LIMITATION OF ARM MOVEMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PERITONITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; ST SEGMENT ELEVATION; STREPTOCOCCUS PNEUMONIA; SYSTEMIC DISEASE; TREATMENT OUTCOME; ULCER PERFORATION;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; MALE; PLACEBOS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 79960332418     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.031     Document Type: Article

References (24)

1. 23-valent pneumococcal polysaccharide vaccine WHO position paper. Wkly Epidemiol Rec 2008, 83(42):373-384.
2. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 1997; 46(RR-8):1-24.
3. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, 1:CD000422.
4. de Roux A., Schmöele-Thoma B., Siber G.R., Hackell J.G., Kuhnke A., Ahlers N., et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008, 46(7):1015-1023.
5. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18):1737-1746.
6. Centers for Disease Control and Prevention Active Bacterial Core surveillance (ABCs) report: emerging infections program network: Streptococcus pneumoniae 2005, [accessed 18.01.2011]. http://www.cdc.gov/abcs/reports-findings/survreports/spneu05.pdf.
7. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294(16):2043-2051.
8. Scott D., Ruckle J., Dar M., Baker S., Kondoh H., Lockhart S. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int 2008, 50(3):295-299.
9. Scott D.A., Komjathy S.F., Hu B.T., Baker S., Supan L.A., Monahan C.A., et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007, 25(33):6164-6166.
10. Honkanen P.O., Keistinen T., Kivelä S.L. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Int Med 1996, 156(2):205-208.
11. Kaine J.L., Kivitz A.J., Birbara C., Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007, 34(2):272-279.
12. Hak E., Grobbee D.E., Sanders E.A., Verheij T.J., Bolkenbaas M., Huijts S.M., et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008, 66(9):378-383.
13. Wernette C.M., Frasch C.E., Madore D., Carlone G., Goldblatt D., Plikaytis B., et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003, 10(4):514-519.
14. Horne A.D., Lachenbruch P.A., Getson P.R., Hsu H.S. Analysis of studies to evaluate immune response to combination vaccines. Clin Infect Dis 2001, 33(Suppl 4):S306-S311.
15. Siber G.R., Chang I., Baker S., Fernsten P., O'Brien K.L., Santosham M., et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007, 25(19):3816-3826.
16. The European Agency for the Evaluation of Medicinal Products Note for guidance on harmonisation of requirements for influenza vaccines 12 March 1997, [accessed 18.01.2011] CPMP/BWP/214/96. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
17. Chan I.S., Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics 1999, 55(4):1202-1209.
18. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19(3):187-195.
19. Plikaytis B.D., Carlone G.M. Statistical considerations for vaccine immunogenicity trials Part 2: noninferiority and other statistical approaches to vaccine evaluation. Vaccine 2005, 23(13):1606-1614.
20. Baxter R., Jeanfreau R., Block S.L., Blatter M., Pichichero M., Jain V.K., et al. A phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J 2010, 29(10):924-930.
21. Lum L.C., Borja-Tabora C.F., Breiman R.F., Vesikari T., Sablan B.P., Chay O.M., et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2010, 28(6):1566-1574.
22. European Influenza Surveillance Scheme. EISS Weekly Electronic Bulletin. Available at: http://www.eiss.org.
23. Vyas J.M., Van der Veen A.G., Ploegh H.L. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008, 8(8):607-618.
24. Vidor E. The nature and consequences of intra- and inter-vaccine interference. J Comp Pathol 2007, 137(Suppl 1):S62-S66.